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Background: Immune thrombocytopenia (ITP) is a childhood disorder that is often life-altering for children and
their parents. Health related quality of life (HRQL) has never been chronologically monitored in children with ITP.
We initiated a prospective study to assess HRQL from diagnosis to six months and define factors that influence this
outcome in children with ITP.
Methods: 73 children with acute ITP aged from 2 to 18 years were prospectively enrolled in the study. According
to the presence of bleeding, they were or were not given a 4-day course of corticosteroid treatment. The PedsQL™
4.0 Generic Core Scale was completed by children and parents upon their inclusion in the study and 6 months after
diagnosis.
Results: Over the six month period, quality of life improved in terms of their global, physical and psychosocial
well-being for 54.5%, 35.6% and 36.2% of patients respectively. This improvement is clinically relevant compared to
scores at diagnosis, corresponding at least to a minimal clinically important difference (MCID). Factors such as sex, age,
platelet count, bleeding scores, bone marrow aspiration and persistence of ITP at 6 months were not significantly
associated with HRQL scores. However, preceding viral infection was identified to have an impact on HRQL.
Conclusions: This first longitudinal study assessing HRQL in children with ITP reveals a global improvement in
PedSQL™ 4.0. However, these results should be considered with caution since our data also confirm that
self-report HRQL scores are not influenced by any analyzed biologic or clinical parameters. Others tools, such as
Kids’ ITP Tools, would probably be required to assess the HRQL of this population.
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And Platelet count above 20 × 109/L.
II Bruising, petechiae of skin or occasional epistaxis.
Little or no interference with daily living.
And Platelet count above 10 × 109/L.
III Bruising, petechiae of skin.
Mucosal lesions.
Epistaxis requiring wicking and hemorrhage.
And Platelet count above 10 × 109/L.
IV Bleeding: epistaxis, melena and/or hemorrhage
requiring hospitalization and/or transfusion.
Serious interference with quality of life.
Or Platelet count below 10 × 109/L and/or
haemoglobin decrease over 2 g/dl.
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Immune thrombocytopenia (ITP) is a relatively uncom-
mon auto-immune disorder in childhood (estimated inci-
dence of 4 to 5 per 100,000 person-years) characterized by
an acquired decrease in circulating platelets [1,2]. Severe
morbidity and mortality are rare and occur in approxi-
mately 0.1% to 3% of patients [3,4]. In more than 70% of
cases, the disease resolves itself within six months, regard-
less of the treatment given [5]. The decision to treat and
the type of treatment are controversial, since among the
different medications available, none has proven its super-
iority regarding reduction in bleeding complications or
transition to chronicity [6-9]. Furthermore, profound
thrombocytopenia, the risk of intracranial bleeding, and
the appearance of bruises may seriously influence lifestyle,
school functioning and physical activities and frequently
result in anxiety in children and parents. Therefore, since
the benefit-risk ratio of current medications is unclear
[7,8] and as the psychological and the physical burden
of the disease is highly variable, it appears necessary to
develop new tools to better understand the exact impact
of the disease on daily life. Although treatment decision-
making depends essentially on the physician’s experience,
it seems of interest to include in this reflection a measure-
ment of quality of life. In this context, evaluation of health
related quality of life (HRQL) could be considered in
ITP, as in numerous chronic diseases, as a method to
provide information about the effects of medical inter-
ventions [10,11].
Recently, an International Working Group of recog-
nized experts defined standard terminology of primary
ITP and criteria of outcome and response [12]. Special
attention was paid to the importance of developing
specific HRQL tools to assess the impact of ITP on the
child’s life. To date, few studies assessing this issue in
ITP are available [13,14]. A disease-specific measure of
HRQL for children with ITP, the Kids’ ITP Tools (KIT),
was validated first in North America [15]. This measure
has recently received cross-cultural validation in several
countries and shows promise for use in international
trials [16]. Contrary to disease-specific tools, generic
measures do not focus on the specific troubles associ-
ated with the disease, but are applicable across different
populations and health states, allowing comparison with
the healthy population. Both are complementary and
thus recommended for the full assessment of HRQL
[17]. While processing the validation of the KIT, we
initiated a study on a different pediatric cohort which is
the first prospective attempt to assess the well-being of
children with ITP from diagnosis to six months with the
generic PedsQL™ 4.0 Generic Core Scales. The following
key questions were addressed: is the HRQL of patients
with ITP impaired at diagnosis and six months later, in




From January 2007 to May 2009, 73 children and ado-
lescents aged from 2 years to 18 years with ITP were
enrolled in this prospective study. They were recruited
in seven pediatric centers of the region Pays de Loire,
France. Patients were eligible if parental consent was
obtained and if they did not have any concomitant disease
that could impact their quality of life. If they were old
enough, the child’s assent was also obtained. The study
was approved by the comité de protection des personnes.
A single reference protocol was set up within each hos-
pital, using a short-term corticosteroid therapy (4 mg/kg
per day during 4 days, with a maximum dose of 180 mg
per day) as the standard first-line treatment. The severity
of ITP was stratified into four distinct groups, according
to the platelet count and the existence of hemorrhagic
signs, based on the consensus developed by the Intercon-
tinental Childhood ITP Study Group (ICIS) (Table 1) [18]
which we chose over the Buchanan score although the
latter remains widely used [19]. Stages I and II do not
require treatment and were subjected to clinical obser-
vation. Patients with stage III could either receive a 4-day
course of corticosteroid or be subjected to simple surveil-
lance, as judged appropriate by the treating physician. For
stage IV, the first-line treatment was methylprednisolone
or prednisone. Bone marrow aspiration was not required
before initiation of corticosteroid therapy if an experi-
enced practitioner could attest to the absence of signs of
malignancy with normal blood cell smear. In cases of
failure to respond to the initial corticosteroid treatment,
or secondary recurrence, an infusion of intravenous
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tered at 48-hour intervals if necessary. After diagnosis
(D1), patients had outpatient follow-up visits at 1 month
(M1), 3 months (M3) and 6 months (M6). Complete blood
count, physical examination, adverse effects and ICIS
bleeding scores were collected at each visit. Complete
response was defined as a platelet count above 100.109/L.
If the patient relapsed, observation, corticosteroid therapy
or IVIG could be considered according to the ICIS score,
previous treatment, and the physician’s practice.
Quality of life
Quality of life was assessed by the PedsQL™ 4.0 Generic
Core Scales. The PedsQL™ 4.0 Generic Core Scales is a
generic questionnaire that measures HRQL by a self-
report and/or a parent-proxy report for patients aged
from 2 to 18 years: HRQL of patients under 5 years is
exclusively measured by the parent proxy-report [20]. It
was completed independently, at D1, M1, M3 and M6,
by parents and children. D1 corresponds to the diagnosis
day and also, generally, to the initiation of treatment. For
younger children, an assistant was appointed to explain
instructions and answer questions. Parent proxy-reports
and age-specific child self-reports were similar versions,
with formulations appropriate to the understanding of the
responder. This questionnaire has been widely used in
previous studies and its validity and reliability has been
well demonstrated [20-22].
Statistical analyses
We compared ITP children and parents mean PedsQL
scores to previously published scores for the healthy refer-
ence population [20,21,23]. Independent sample t-tests
were used to compare scores. Impaired HRQL was defined
as a PedsQL score at least 1 standard deviation (SD) below
the healthy sample mean score. Original norm data
from a sample of healthy children was used as reference
and scores from french healthy children were provided
for information [21-24].
The percentages of scores at the extremes of the score
scale, the floor value (minimum possible score i.e. 0) and
the ceiling value (maximum possible score i.e. 100), were
described to explore the ability for ITP children to dis-
tinguish variations in quality of life. The ceiling effect is
defined as an inability for children who had the max-
imum possible score to get a better score when a subse-
quent assessment is performed (the floor effect is the
same phenomenon but with scores at the low end).
Intraclass Correlation coefficients (ICC) were used to
describe agreement between child self-report and parent
proxy-report across age subgroups. Intraclass Correlation
Coefficients are designated as ≤ 0.40 for poor to fair agree-
ment, 0.41–0.60 for moderate agreement, 0.61–0.80 for
good agreement, and 0.81–1.00 for excellent agreement.The minimal clinically important difference (MCID)
concept was used to explore improvement in quality of
life between diagnosis and M6. MCID is defined as the
smallest difference in a PedsQL score of a domain of
interest that each patient perceives to be beneficial and
that would mandate a change in the patient’s management
[21]. MCID scores were computed by using the Standard
Error of Measurement (SEM) of scores at diagnosis. SEM
was computed by multiplying the standard deviation by
the square root of 1-alpha (Cronbach alpha coefficient).
Excellent agreements between the SEM and MCID were
shown in the literature [25,26]. Improvement in quality of
life was defined as the score at M6 corresponding to the
score at diagnosis with an improvement at least equal to
the value of the MCID score.
Potential predicting factors that impact improvement in
quality of life at M6 as previously defined were determined
by univariate logistic regression. The associations are pre-
sented as beta coefficients with standard error (SE) derived
from logistic regression. Given the exploratory nature of
this analysis, we did not perform multivariate analyses.
Statistical analyses were conducted using Stata software
(version 12.1; StataCorp, Texas).Results
Characteristics of patients
Between January 2007 and May 2009, 97 children were
diagnosed with primary ITP in the region Pays de Loire.
Among them, 16 children under 2 years of age were not
eligible to be enrolled in the study because of age. Ul-
timately, 81 families were asked to complete the proxy
and/or self-report version of the PedsQL™ 4.0 Generic
Core Scales.
For the 34 children < 5 years, HRQL was exclusively
measured by the parent proxy-report. Among the 47
self-reports of children > 5 years and the 81 parent-proxy
reports, 8 reports in each group were partially uncom-
pleted for more than 50% of the items. Therefore, accord-
ing to the PedsQL™ 4.0 recommendations, these reports
were considered as ineligible for the study. Finally, 73
children were included for analysis in the study: 34 aged
2 to 5 years, 39 aged 5 to 18 years, and 73 parents.
Major characteristics of the 73 children at diagnosis are
summarized in Table 2.
Initial treatments consisted in corticosteroids for 39
patients (53.5%) and IVIG for 9 patients (12.3%) while a
wait-and-watch approach was used in 25 patients (34.2%).
Between 3 and 6 months of follow up, 2 patients received
IVIG only, 4 received corticosteroids only and 2 received
IVIG and corticosteroids. After 6 months, platelet count
was <100.109/L in 26/69 patients (37%) including 11/42
patients under 10 years (26.1%) and 15/27 patients over 10
years (55.5%) (p = 0.1).
Table 2 Characteristics of ITP patients at diagnosis
Characteristics Diagnosis
Patients, n 73




Preceding viral infection, n (%) 44 (60.2%)
ICIS scores, n (%)
Score I 5 (6.9%)
Score II 22 (30.1%)
Score III 2 (2.7%)
Score IV 44 (60.3%)
Initial place of treatment, n (%)**
In patient 52 (71.3%)
Observation unit* 10 (13.7%)
Outpatient 11 (15%)
Initial bone marrow examination, n (%) 11 (15%)
Initial treatment, n (%)
No treatment 25 (34.2%)
Corticosteroid 39 (53.5%)
IVIG 9 (12.3%)
n: number of patients; IVIG: intravenous immunoglobulin;
*An observation unit is a unit of short hospital stay dedicated to
diurnal monitoring.
**Although they were score I or II, some patients were not subjected to clinical
observation and received treatment.
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The main results concerning HRQL during the evolution
of ITP are summarized in Table 3. The psycho-social
summary score includes emotional, social and school
functioning. Since we thought that change in scores
between D1 and M6 were more suitable for assessing
the evolution of HRQL, we mainly focused our analysis
on these points.
We compared self-reported and parent-proxy global,
physical and psycho-social mean scores of our ITP popu-
lation to the mean scores of the US population (original
norm data) and the mean scores of the French population.
At study onset, no difference was found regardless of the
healthy population reference since scores observed in the
population on study did not range below SD compared to
the healthy population scores. However, when compared
to the US population, we noted lower mean scores at diag-
nosis in patients with ITP for emotional functioning and
school functioning (respectively 72.6 versus 79.3 and 74
versus 81.1), but these results were not found when com-
pared to the French population (respectively 72.6 versus
69.8 and 74 versus 76.4). In the same way, mean scores for
parent-proxy reports, emotional functioning at diagnosis
were lower than in the healthy population when comparedto US population (71.1 versus 81.3) while they were the
same when compared to the French population (71.1
versus 71.8). This reflects the fact that, in the French refer-
ence population, the mean values for emotional, social
and school functioning are generally lower than that of
the US population reference (except for social functioning
in parent-proxy reports), maybe due to cultural differences
between the two populations and to the fact that the two
populations are not exactly similar in term of age.
We studied HRQL scores observed on D1 and M6. As
previously defined, these changes were expressed in term
of MCID, which measures more closely the impact of
differences observed in quality of life. In children's re-
ports, we observed a statistically significant improve-
ment in HRQL scores from D1 to M6 only for global
and emotional scores (Δ respectively 4.5 for an expected
MCID score 4.3 and 9.4 for an expected MCID score
8.3). No statistically significant differences were found
in parent-proxy reports (Δ <MCID for all items). The
percentages of patients that presented a PedsQL score
perceived to be beneficial (score at M6 at least equal to
the value of MCID) in terms of global, physical and psy-
chosocial score were respectively 54.5%, 35.6% and
36.2%. In the same way, the proportion of patients that
presented a PedsQL score perceived to be beneficial in
term of emotional, social and school functioning were
respectively 42.1%, 28.5% and 32.1%.
There was no minimal floor effect for ITP children.
However, ceiling effects existed. Ceiling effects for healthy
children highly satisfied with their quality of life were re-
ported in the literature but with much greater proportions
compared to ITP children at diagnosis [21].
ICC between child and parent reports (Table 4) seemed
better in M6 than at inclusion, with a better correlation in
older children (more than 13 years old). For these teen-
agers, the main differences related to the physical score
and the school functioning (upon inclusion) and the social
and emotional functioning (in M6). The ICC between
child self-report and parent proxy-report was measured as
moderate to excellent.
To determine their influence on HRQL scores and
MCID, several parameters were analyzed: gender, age at
diagnosis, preceding viral infection, initial ICIS score, ini-
tial place of treatment, and platelet count on M6. Change
in quality of life was measured by MCID score (Table 5).
Patients with an initial hospitalization had a lower score in
social functioning (75% vs 25%, p = 0.05) and patients with
a preceding viral infection perceived an improvement of
quality of life (73.3% vs 26.7%, p = 0.05) in term of global
score, at least equal to the MCID score at M6. In contrast,
there was no statistically significant difference related to
gender, age and ICIS score at diagnosis or initial treat-
ment. Platelet count at M6 (< or >100.109/L) did not
affect the MCID either.








France2 (n = 185)
Mean SD % floor % ceiling Cronbach α
coefficient
MCID Mean SD % floor % ceiling Mean SD Mean SD
Children
Global score 80.6 10.7 0.0 0.0 0.83 4.3 85.1 16.2 0.0 10.8 4.5* 83.8 12.6 77.6 12.5
Physical
summary score
86.0 10.4 0.0 22.0 0.88 3.6 88.4 12.7 0.0 33.3 2.4 87.5 13.5 81.6 13.5
Psychosocial
summary score
77.7 14.1 0.0 0.0 0.71 7.6 84.1 13.9 0.0 10.8 6.4 81.9 14.0 75.5 14.3
Emotional
functioning
72.0 18.6 0.0 12.8 0.80 8.3 81.4 17.8 0.0 27.0 9.4* 79.3 18.1 69.8 18.4
Social
functioning
86.4 16.2 0.0 30.0 0.81 7.0 90.7 13.8 0.0 48.6 4.3 85.1 16.7 80.5 17.9
School
functioning
74.0 16.2 0.0 5.1 0.77 7.7 79.9 17.6 0.0 16.6 5.9 81.1 16.4 76.4 16.6
Parent
Global score 82.7 12.3 0.0 4.1 0.85 4.6 87.2 12.5 0.0 14.5 4.5 82.7 15.4 80.4 12.1
Physical
summary score
87.2 14.3 0.0 30.1 0.86 5.3 90.8 13.1 0.0 42.8 3.6 84.5 19.5 85.7 13.7
Psychosocial
summary score
80.2 14.0 0.0 5.5 0.76 6.8 85.2 13.4 0.0 14.5 5 81.7 15.2 77.4 13.2
Emotional
functioning
71.1 19.5 0.0 12.6 0.83 8.1 77.5 20.1 0.0 22.2 6.4 81.3 16.5 71.8 16.3
Social
functioning
89.5 14.2 0.0 47.2 0.84 5.5 93.5 11.6 0.0 66.0 4 83.7 19.4 84.4 16.2
School
functioning
80.6 18.1 0.0 24.6 0.82 7.6 86.1 14.3 0.0 30.1 5.5 78.8 19.6 76.1 16.7
% Floor/Ceiling = the proportion of scores at the extremes of the scaling range/SD = Standard deviation. Impaired health-related QOL was defined as a score that
was more than 1 SD below the healthy sample mean/MCID =Minimal Clinically Important Difference. Standard Error of measurement computed by multiplying
the standard deviation at diagnosis by the square root of 1 - alpha (Cronbach alpha coefficient)/Δ = the difference between mean scores at diagnosis and month
6. An improvement in quality of life between diagnosis and month 6 requires a Δ at least equal to the value of MCID score.
*p < 0.01.
1Varni et al., 2007: correspond to the standards obtained from a population of 5480 healthy US children ().
2Tessier et al., 2009.
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In recent years, measurement of HRQL has become
more important in the assessment of several pediatric
diseases, including ITP. The lack of evidence that any of
the current treatments can modify either the short or
long-term outcomes in children with ITP generated
interest in assessing HRQL in this population. This study
aimed to determine the impact of ITP on children’s
HRQL from diagnosis to six months after diagnosis and
to identify any risk factors.
Considering the first objective, we observed a slightly
lower score for baseline emotional functioning in parent-
proxy and self reports as well as the school functioning in
self-reports when compared to original norm data. Sur-
prisingly, this difference was not found when the compari-
son was performed with the French healthy population
[22]: results were generally even higher than in the healthy
population for most items. The fact that children enrolled
in the French reference population were older than those
of our study could be one of the possible explanation forthis difference, as younger children are less likely to worry.
But this does not explain all the differences observed in
parent-proxy reports. These differences were not sufficient
to be considered as an impairment, nor a minimal clinic-
ally important in terms of quality of life. We did not
observe any difference of HRQL between self or parent-
proxy-reports and the original norm data after 6 months
of ITP evolution either. The results are not surprising as
ITP is a blood disease which causes considerable worry
about both rare but serious bleeding and having a more
serious condition. Over the following months, most pa-
tients (children and parents) experienced an improvement
of HRQL and at M6 quality of life was the same as the
healthy population. On all major parameters, HRQL
scores increased between D1 and M6 and, considering
the global score, the majority of patients (54.5%) per-
ceived a change in quality of life as measured by MCID.
This was an expected result as it coincides with the
natural favorable evolution of the disease [8-27]. In our
cohort, as in previous reports, about two thirds of
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ICC (intraclass correlation coefficients) are designated as < =0.4 poor to fair agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good agreement, and 0.81-1.00
excellent agreement.
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months and bleeding scores improved with time in the
majority of the patients. We can also hypothesize that
the knowledge concerning ITP that parents and children
develop over time, helps reduce their anxiety [28]. Inter-
estingly, significantly lower ICC was noted for children of
5 to 7 years old, especially for emotional functioning at
diagnosis and for social and school functioning at M6, as
already mentioned in the literature [22]. More generally
this difference is observed in the global score with better
agreement for children of more than 13 years old. Al-
though MCID does not significantly differ depending on
age, these data could suggest a trend for young children to
be more affected by ITP. The strict limitation of the child’s
activities enforced by the parents to protect them from
serious injuries could be one of the major reasons for their
stress and their parents’ concern, which lead to a lower
score. On the other hand, in older children, one can also
speculate that HRQL self-report results are a representa-
tion of the sense that teenagers might believe themselves
to be invincible.
Considering the second end-point, from our results, a
lower score in social functioning seemed to be associated
with an initial hospitalisation and the quality of life per-
ceived in term of global score at M6 was associated with a
viral infection before ITP (Table 5). Other variables such
as age, platelet count at diagnosis and 6 months, initial
bleeding scores or initial treatment did not influence
scores of children or parents. This result is consistent with
the findings of Neunert et al. who found only weak and
non-significant negative correlations between bleeding se-
verity or platelet count at diagnosis and HRQL [14]. Inour series about two thirds of patients had an initial ICIS
score ≥ III with a platelet count < 10.109/L, with both
variables improving with time, lowering anxiety of par-
ents and children. Conversely, a recent viral infection
could potentially have symptoms affecting the child’s
HRQL, with a subsequent improvement in HRQL once
the infection resolves, explaining the significant change
in the MCID between D1 and M6. Similarly, the initial
hospitalization would impact on HRQL, regardless of
the reason for hospitalization. So, these two factors (viral
infection and initial hospitalization) appear to effect the
MCID independently of ITP.
Some limitations in our study should be pointed out.
First, the limited size of our cohort did not allow us to
analyse clinically relevant subgroups of patients such as
those with persistent ITP at M6, with regular physical
activity or patients from different socio-professional ori-
gins. Second, patients were recruited from seven pediatric
treatment centers. These various origins may have induced
a clustering effect of HRQL according to the medical and
paramedical speech at diagnosis and through-out the
follow-up. Third, we did not differentiate assessments of
mothers and fathers. We can speculate that parents can
have different evaluations of their own child quality of
life. Fourth, a significant number of patients had an ini-
tial ceiling effect at 100: in such a condition, we cannot
detect any improvement in quality of life during follow-
up. Finally, although PedSQL™ 4.0 is an international
tool, translated and linguistically validated in French,
there is, to our knowledge, only one study establishing
references in a French healthy population of 185 chil-
dren [22]. We compared our results to those published
Table 5 Factors associated with Minimal Clinically Important Difference (MCID) between health related quality of life











β SE p β SE p β SE p β SE p β SE p β SE p
Gender
Female 0.32 0.54 0.55 0.28 0.54 0.59 −0.06 0.54 0.90 −0.01 0.53 0.97 −0.02 0.59 0.73 −0.54 0.57 0.34
Male Ref Ref Ref Ref Ref Ref
Age
2 - 4 years 0.51 0.63 0.41 0.44 0.59 0.45 1.05 0.71 0.14 0.65 0.59 0.27 −0.24 0.60 0.68 0.92 0.68 0.17
5 - 7 years −0.02 0.72 0.96 1.28 1.08 0.23 0.74 0.97 0.45 1.28 1.08 0.23 1.08 1.03 0.29 −0.03 1.02 0.97
8 - 12 years −0.35 0.58 0.54 0.13 0.41 0.75 −0.47 0.45 0.29 0.10 0.40 0.80 −0.34 0.44 0.44 −0.05 0.46 0.99
13 - 18 years −0.69 0.57 0.22 −0.24 0.49 0.61 −0.44 0.51 0.38 0.66 0.58 0.25 −0.37 0.54 0.49 −1.52 0.83 0.06
Age < =10 years 0.77 0.57 0.18 −0.22 0.54 0.68 −0.28 0.55 0.60 −0.55 0.54 0.30 0.20 0.60 0.73 0.01 0.57 0.98
Preceding viral infection 1.25 0.57 0.03 0.48 0.58 0.4 0.78 0.61 0.20 −0.18 0.56 0.74 −0.96 0.61 0.11 0.82 0.65 0.20
ICIS scores
Score I Ref Ref Ref Ref Ref Ref
Score II −15.2 109 0.98 14.5 198 0.99 14.4 208 0.99 14.8 203 0.99 15.4 331 0.99 13.52 167 0.99
Score III or IV −14.9 109 0.98 14.6 198 0.99 14.9 208 0.99 15.01 203 0.99 15.25 331 0.99 14.39 167 0.99
Initial place of treatment
Inpatient 0.15 0.87 0.86 −0.87 0.74 0.23 −0.39 0.74 0.59 0.53 0.77 0.48 −1.45 0.77 0.05 1.49 1.11 0.17
Observation unit 0.22 1.05 0.83 −1.32 1.05 0.21 −0.87 1.05 0.40 0.18 1.01 0.85 −1.83 1.28 0.15 1.16 1.35 0.38
Outpatient Ref Ref Ref Ref Ref Ref
Initial treatment
Corticosteroid 0.81 0.60 0.17 −0.02 0,59 0.96 0.77 0.63 0.22 0.13 0.58 0.81 −0.02 0.66 0.96 1.21 0.72 0.09
IVIG 0.60 0.89 0.49 0.33 0.89 0.71 0.81 0.92 0.37 0.11 0.88 0.89 1.02 0.96 0.28 1.67 1.03 0.10
No treatment Ref Ref Ref Ref Ref Ref
Platelets
Platelets >100000 at month 6 0.67 0.57 0.23 0.12 0.56 0.82 0.20 0.57 0.71 −0.19 0.56 0.72 0.21 0.62 0.73 0.65 0.59 0.27
ref = reference/β coefficients and SEs from logistic regression such that positive β coefficient means that predictor or increasing values of predictor are associated
with better quality of life with MCID.
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ences observed (Table 3) raise the question of the validity
of some of our comparisons especially as the validation
performed by Tessier et al. [22] was conducted among
school children (over 5 years). As emphasized by these
authors, further work would probably be required in the
French population to determine real reference values
for PedSQL™ 4.0.
However, despite these limitations, we think it important
to note that ITP does not significantly affect HRQL as
measured by the PedSQL™ 4.0. Even if we observe an ini-
tial decrease in scores (especially in the psychosocial field),
it remains moderate and quickly corrected within 6
months after diagnosis. We can wonder if the PedsQL™
4.0 Generic Core Scales is a sufficient tool to measure
HRQL in children with ITP. Recently, Klaassen et al. [16]
performed a cross-culturally translated KIT (Kids’ ITP
Tools) validation. This tool is specifically designed to
measure HRQL in children with ITP. Its validity wasassessed by a recent study in four countries and French
newly diagnosed patients, different from those reported
here, were enrolled in this study [16]. In the whole study
population, the authors note that the KIT scores are mod-
erately correlated with the PedsQL scores. Taking into ac-
count these results and our own results, we think it would
be interesting to study the quality of life of these patients
with a larger cohort.
Conclusions
This longitudinal study assessing HRQL in children with
ITP reveals a global improvement in PedSQL™ 4.0 scores
from diagnosis up to six months of follow up, but these var-
iations are not sufficient to indicate significant changes in
quality of life. Our data also confirm that self-reported
HRQL scores are not influenced by any analyzed biological
or clinical parameters. However, further studies using a
disease-specific measure, such as the Kids’ ITP Tools, will
certainly provide more information on HRQL.
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